Ashraf Badros, M.B., Ch.B., a nationally recognized expert in multiple myeloma, offers perspective in an editorial in the May 10 issue of the New England Journal of Medicine accompanying three major clinical trials investigating lenalidomide maintenance therapy in multiple myeloma. The editorial discusses the significance of the studies in the treatment of multiple myeloma patients and the future of maintenance trials. All three clinical trials involved newly diagnosed multiple myeloma patients. In two of the three trials, the initial treatment was a stem cell transplant. All three trials reported significant improvement in time to progression in lenalidomide maintenance groups. Only one of the three trials, however, found that maintenance therapy improved the overall survival of patients.
In the editorial, Dr. Badros notes that additional data are needed before the drug can be accepted as a standard of care for myeloma patients. Read more